Alert Frequency, Nurse, and Patient Satisfaction With a wCVSM Software Across Health Care Systems and Cultures
1 other identifier
observational
100
5 countries
5
Brief Summary
The goal of this prospective, international multi-centre pilot study is to assess the functionality and user experience of a new vital sign monitoring system in 20 patients and 20 nurses in the general ward at each centre. The patients will be monitored with a wireless, continuous vital sign monitoring systems and answer a questionnaire afterwards. They will in addition have vital signs monitored as per standard practice. The nurses will answer a questionnaire after having had the responsibility for a monitored patient for a full shift. The main aims are: To determine the frequency of alerts activated in the app in relation to the alerts that should be activated based on measured data, to explore current practices of in-hospital monitoring by semi-structured interviews to map differences across systems and to test nurse and patient satisfaction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2024
Typical duration for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 22, 2024
CompletedStudy Start
First participant enrolled
February 26, 2024
CompletedFirst Posted
Study publicly available on registry
March 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
August 12, 2025
August 1, 2025
2.4 years
January 22, 2024
August 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Frequency of alerts activated in the app in relation to the alerts that should be activated based on measured data
during monitoring period, on average 3 months
Secondary Outcomes (12)
Technical feasibility
during monitoring period, on average 3 months
Alert relay to smartphones
during monitoring period, on average 3 months
Response to alerts
during monitoring period, on average 3 months
Patients experiences from being monitored with wCSVM.
during monitoring period, on average 3 months
Relevance of alarms
during monitoring period, on average 3 months
- +7 more secondary outcomes
Other Outcomes (7)
Cumulative duration of SpO2<88% and SpO2 < 85%
during monitoring period, on average 3 months
Cumulative duration of respiratory rate ≤ 5 min-1 and Respiratory rate > 24 min-1
during monitoring period, on average 3 months
Cumulative duration of Heart rate > 130 min-1 and Heart rate ≤ 30 min-1
during monitoring period, on average 3 months
- +4 more other outcomes
Eligibility Criteria
20 Patients in the general ward (surgical or medical) will be monitored with wCVSM and answer a questionnaire afterwards. 20 nurses will answer a questionnaire after having had the responsibility for a monitored patient for a full shift (including a shift where monitoring is initiated or a shift where the patient is discharged). Therefore, multiple nurses can be interviewed per patient. Patients will in addition have vital signs monitored as per standard practice. Participants will be recruited from wards at the study sites.
You may qualify if:
- Adults (≥18 years)
- Expected stay in the hospital ≥2 days
- Admitted for surgery with expected duration of surgery \>2 hours or admitted for acute medical condition with at least one of the following vital sign deviations within 24 hours of acute admission, recorded by the staff
- RR \> 21 breaths pr minute
- RR \< 11 breaths pr minute
- Pulse (P) \> 91 beats pr minute
- Pulse (P) \< 50 beats pr minute
- SpO2 \< 94 % without oxygen supplementation
- Systolic BP \< 110 mmHg
- Systolic BP \> 220 mmHg
You may not qualify if:
- Participant expected not to cooperate with study procedures.
- Allergy to plaster or silicone.
- Pacemaker or Implantable Cardioverter Defibrillator (ICD) device.
- Inability to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Christian S. Meyhofflead
- Rigshospitalet, Denmarkcollaborator
Study Sites (5)
The Cleveland Clinic Foundation, General Anesthesiology
Cleveland, Ohio, 44195, United States
Universitätsklinikum Hamburg-Eppendorf (UKE), Zentrum für Anästhesiologie und Intensivmedizin, Klinik und Poliklinik für Anästhesiologie
Hamburg, 20246, Germany
University Medical Center Groningen, Department of Anesthesiology
Groningen, 9700, Netherlands
St. Olavs Hospital HF, Klinikk for anestesi og intensivmedisin
Trondheim, 7006, Norway
Liverpool University Hospitals NHS Foundation Trust
Liverpool, L7 8YE, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christian S Meyhoff, MD, PhD
Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
- PRINCIPAL INVESTIGATOR
Eske K Aasvang, MD, DMSci
Rigshospitalet, Copenhagen University, Copenhagen, Denmark
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor, PhD
Study Record Dates
First Submitted
January 22, 2024
First Posted
March 4, 2024
Study Start
February 26, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
August 12, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share